4DMT to Present Interim Data from 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis Lung Disease at the European Cystic Fibrosis Society (ECFS) 46th Annual Meeting

Interim data to be presented in an oral presentation by Dr. Jennifer L. Taylor-Cousar, MD, MSCS at the 2023 ECFS Annual Meeting in Vienna, Austria on Thursday, June 8, 2023 at 5:00 p.m. CET Company to... | May 24, 2023

Related Keywords

Austria ,Vienna ,Wien ,United States ,Jenniferl Taylor Cousar ,Julian Pei ,Katherine Smith ,Exchange Commission ,Corporate Communications ,Nasdaq ,National Jewish Health ,European Cystic Fibrosis Society ,Cystic Fibrosis Foundation Therapeutics Development Center ,Adult Cystic Fibrosis Program ,Cf Foundation ,Molecular Therapeutics ,Annual Meeting ,Cystic Fibrosis Questionnaire Revised ,Respiratory Domain Score ,Clinical Data Webcast ,Presentation Details ,Lead Principal Investigator ,Scientific Presentations ,Cystic Fibrosis Lung ,Therapeutic Vector Evolution ,Nobel Prize Winning ,Looking Statements ,Private Securities Litigation Reform Act ,Molecular Therapeutic ,Annual Report ,Investor Relations ,4d Molecular Therapeutics ,Nc Stock Exchange ,News ,Information ,Press Release ,Interim ,Data ,O ,The ,Resented ,N ,Mural ,Presentation ,Y ,Jennifer ,Scs ,It ,He ,023 ,Cfs ,Nnual ,Meeting ,Pune ,Pet ,Ompany Fdmt Us35104e1001 ,